Pharming Group N.V. (FRA:PHG)

Pharming Group Statistics

Total Valuation

Pharming Group has a market cap or net worth of EUR 946.19 million. The enterprise value is 916.15 million.

Market Cap	946.19M
Enterprise Value	916.15M

Important Dates

The next estimated earnings date is Thursday, April 2, 2026.

Earnings Date	Apr 2, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-2.65%
Shares Change (QoQ)	-26.83%
Owned by Insiders (%)	2.11%
Owned by Institutions (%)	17.33%
Float	670.71M

Valuation Ratios

The trailing PE ratio is 2,906.17 and the forward PE ratio is 23.83.

PE Ratio	2,906.17
Forward PE	23.83
PS Ratio	3.06
PB Ratio	4.19
P/TBV Ratio	8.56
P/FCF Ratio	21.06
P/OCF Ratio	20.82
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 21.27, with an EV/FCF ratio of 20.39.

EV / Earnings	2,813.91
EV / Sales	2.97
EV / EBITDA	21.27
EV / EBIT	26.41
EV / FCF	20.39

Financial Position

The company has a current ratio of 3.16, with a Debt / Equity ratio of 0.49.

Current Ratio	3.16
Quick Ratio	2.39
Debt / Equity	0.49
Debt / EBITDA	2.55
Debt / FCF	2.48
Interest Coverage	2.90

Financial Efficiency

Return on equity (ROE) is 0.03% and return on invested capital (ROIC) is 6.92%.

Return on Equity (ROE)	0.03%
Return on Assets (ROA)	5.76%
Return on Invested Capital (ROIC)	6.92%
Return on Capital Employed (ROCE)	10.74%
Revenue Per Employee	764,273
Profits Per Employee	806
Employee Count	404
Asset Turnover	0.81
Inventory Turnover	0.57

Taxes

In the past 12 months, Pharming Group has paid 12.49 million in taxes.

Income Tax	12.49M
Effective Tax Rate	99.53%

Stock Price Statistics

The stock price has increased by +50.35% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+50.35%
50-Day Moving Average	11.87
200-Day Moving Average	9.36
Relative Strength Index (RSI)	40.38
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharming Group had revenue of EUR 308.77 million and earned 325,579 in profits. Earnings per share was 0.00.

Revenue	308.77M
Gross Profit	277.59M
Operating Income	35.33M
Pretax Income	12.55M
Net Income	325,579
EBITDA	40.84M
EBIT	35.33M
Earnings Per Share (EPS)	0.00

Balance Sheet

The company has 141.62 million in cash and 111.58 million in debt, giving a net cash position of 30.04 million.

Cash & Cash Equivalents	141.62M
Total Debt	111.58M
Net Cash	30.04M
Net Cash Per Share	n/a
Equity (Book Value)	225.56M
Book Value Per Share	0.45
Working Capital	161.67M

Cash Flow

In the last 12 months, operating cash flow was 45.45 million and capital expenditures -519,903, giving a free cash flow of 44.93 million.

Operating Cash Flow	45.45M
Capital Expenditures	-519,903
Free Cash Flow	44.93M
FCF Per Share	n/a

Margins

Gross margin is 89.90%, with operating and profit margins of 11.44% and 0.11%.

Gross Margin	89.90%
Operating Margin	11.44%
Pretax Margin	4.06%
Profit Margin	0.11%
EBITDA Margin	13.23%
EBIT Margin	11.44%
FCF Margin	14.55%

Dividends & Yields

Pharming Group does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.65%
Shareholder Yield	2.65%
Earnings Yield	0.03%
FCF Yield	4.75%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Pharming Group has an Altman Z-Score of 2.65 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.65
Piotroski F-Score	6